Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study

Table 3 Univariate and multivariate analysis for survival in 80 NSCLC patients with LM

	Univariate analysis		Multivariate analysis
	HR (95%CI)	P	HR (95%CI)	P
Gender (female vs. male)	0.950 (0.531 to 1.698)	0.862
Age (< 53.5 vs. ≥53.5)	0.545 (0.301 to 0.987)	0.043	0.492 (0.265 to 0.915)	0.025
KPS (< 80 vs. ≥80)	1.298 (0.640 to 2.632)	0.470
GCS (15 vs. ≤14)	1.126 (0.572 to 2.220)	0.731
Concurrent brain metastasis (yes vs. no)	1.039 (0.585 to 1.846)	0.895
EGFR mutation (yes vs. no)	0.288 (0.159 to 0.522)	0.000	0.390 (0.186 to 0.820)	0.013
EGFR TKI after LM (yes vs. no)	0.260 (0.138 to 0.487)	0.000	0.549 (0.491 to 1.039)	0.053
WBRT (yes vs. no)	0.565 (0.315 to 1.013)	0.053	0.697 (0.373 to 1.306)	0.260
Chemotherapy (yes vs. no)	0.873 (0.480 to 1.589)	0.657
Bevacizumab (yes vs. no)	1.909 (0.677 to 5.386)	0.222

Abbreviations: NSCLC non-small-cell lung cancer, KPS Karnofsky Performance Status, GCS Glasgow Coma Scale, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitors, LM leptomeningeal metastasis, WBRT whole brain radiotherapy, Gy gray, HR hazard ratio, CI confidence interval

ISSN: 1748-717X